Overview

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the single dose pharmacokinetics (PK) and safety of TR701 FA in subjects with advance renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Trius Therapeutics LLC
Treatments:
Oxazolidinones
Tedizolid
Tedizolid phosphate
Torezolid
Torezolid phosphate